|
Advertising
Customer Service
• Register
|
MORE FROM NJBIZ
PEOPLE WHO READ THIS...
Also read these stories:
 Related Articles
This Week's Most Read Articles
Most Recent Articles
|
||||||||||
Under the revised deal, Par's profit share from sales of sumatriptan succinate injection, a generic version of GlaxoSmithKline's Imitrex Injection that treats migraines and cluster headaches, will rise from 38 percent to 95 percent.
Shares of Par, a generic drug maker headquartered in Woodcliff Lake, were up $0.17, or 1 percent, to $17.35 in morning trading.
Par said it expects to launch sumatriptan succinate injection in November. GlaxoSmithKline's Imitrex Injection patent expires in February 2009, according to Par.
Irvine, Calif.-based Spectrum settled a patent dispute with GlaxoSmithKline related to Imitrex Injection in November 2006, Par said.
Imitrex Injection has annual sales of about $220 million in the United States, according to IMS Health.
